Introduction

Arsenic is a group 5 metalloid and is renowned for its toxicity. The soluble inorganic forms of arsenic, arsenite (+3) and arsenate (+5), are widespread in terrestrial and aquatic environments, where arsenite is the more toxic and mobile species. The consumption of naturally occurring inorganic arsenic in drinking water has caused poisoning of human populations across regions of West Bengal, Bangladesh, Chile, Taiwan and Vietnam, while anthropogenic activity (principally through the mining of valuable metals) has resulted in arsenic contamination of environments in Canada, USA, Argentina and Australia. Despite its toxicity, certain microbes are capable of gaining energy by oxidising arsenite to arsenate, and this process contributes to the global cycle of arsenic. Certain microbes are capable of gaining energy by oxidising arsenite to arsenate, and this process contributes to the global cycle of arsenic. Biological arsenic oxidation is catalysed by arsenite oxidase (Aio) (see Lett et al. for recent changes to the nomenclature for the arsenite oxidase). Aio is a member of the DMSO reductase family of molybdoenzymes which is a family of redox enzymes that function in a diverse range of prokaryotic electron transport chains. The enzyme is a heterodimer that consists of a large \( \alpha \)-subunit, AioA, and a small \( \beta \)-subunit, AioB. The X-ray crystal structure of the Aio from the mesophilic betaproteobacterium Alcaligenes faecalis has been resolved. The structure shows that AioA contains a 3Fe–4S cluster and a bis-molybdopterin guanine dinucleotide (bis-MGD) cofactor at the active site, while AioB contains a 2Fe–2S Rieske cluster. The Aio is exported to the periplasm by the Twin-arginine translocation (Tat) pathway conferred by an N-terminal signal sequence on AioB. The Aio that have been characterised to date have all been purified from mesophilic arsenite oxidisers (reviewed by Heath et al.).

The Aio operon structure always includes the aioA and aioB genes, with aioB located upstream of aioA. In some arsenite oxidisers of the Alpha- and Betaproteobacteria a cytochrome c-encoding gene (cytC) is located downstream of aioA and this cytochrome has been shown to serve as the electron acceptor to the Aio. Often found upstream of aioB are three genes (aioXSR) whose products are involved in the regulation of arsenite oxidase gene expression. AioS is a sensor histidine kinase and AioR a response regulator. Together with a third...
gene product, AioX, which has been shown to bind arsenite, they are thought to regulate transcription of the *aioBA* operon. Variation is seen in the other genes found in the *aio* cluster. Of the isolated arsenite oxidisers, only *Polaromonas* sp. str. GM1, an aerobic, heterotrophic, betaproteobacterium, has been shown to oxidise arsenite at temperatures below 10 °C. GM1 is also unusual in that *aio* gene expression is constitutive and it oxidises arsenite in the early log-phase of growth whereas most heterotrophic arsenite oxidisers oxidise arsenite in the late-log or stationary phase using arsenite as the secondary energy source. GM1’s Aio is constitutively expressed which may be explained by the environment in which GM1 was isolated, an arsenic-contaminated biofilm that contained about 10 mM arsenic. In the environment in which GM1 was isolated, an arsenic-heterotrophic arsenite oxidisers oxidise arsenite in the late-log or stationary phase using arsenite as the secondary energy source. The GM1 integrase sequence however, did not contain the conserved C-terminal catalytic domain present in the sequences of the closely related phage integrases, indicating that it is unlikely to be functional. The *aioB* gene is found downstream of the partial integrase sequence and encodes an apoprotein of 179 amino acids (18 561 Da). The protein shares closest sequence identity with the AioB homologues in the *Betaproteobacteria* such as *Acidovorax* sp. str. NO-1 (73% identity), *A. faecalis* (57% identity) and *Herminiimonas arsenicoxydans* (61% identity) compared with the alphaproteobacterial sequence from NT-26 (40% identity). The sequence contains a conserved motif involved in binding the Rieske 2Fe–2S cluster and in the case of *A. faecalis* (not in NT-26) conserved residues involved in disulphide bond formation, Cys-X-His-X-Gly-Cys*-X*-Cys-X-Cys*-His (cluster ligands are in italics; the asterisked residues form a disulphide bond which bridges over the cluster, connecting the two cluster-binding loops). In common with all other AioB sequences the GM1 sequence contains a Tat signal sequence (1–36 amino acids) with the conserved RRFLK motif (RRFLK in GM1 AioB) which directs the transport of the fully folded AioB complex to the periplasm via the Tat pathway. A predicted signal cleavage site is present between amino acids 36 and 37 (i.e. ADA-AT) resulting in a processed protein of 14 733 Da. Downstream of *aioB* is *aioA* and it encodes a protein of 827 amino acid (91 690 Da unprocessed and 91 559 Da without N-terminal methionine). The GM1 AioA shares the highest sequence identity with that from *Acidovorax* sp. str. NO-1 (80% identity), *A. faecalis* (70% identity) and *Herminiimonas arsenicoxydans* (69% identity) compared with that from NT-26 (47% identity). The conserved motif, Cys*-X*-Cys*-X*-Cys-X-Ser70 involved in binding the 3Fe–4S cluster, is conserved, as are the amino acids implicated in binding arsenite (i.e. His197, Glu205, Arg421 and His425). Downstream of *aioB* is cytC, which encodes a putative c-type cytochrome of 104 amino acids (10 884 Da unprocessed) and contains a single CX3CH heme-binding motif suggesting the presence of a single heme c. The protein also

**Results and discussion**

GM1 can oxidise arsenite at 0 °C (data not shown) to 20 °C and does so in the early-log phase of growth, which is unusual for heterotrophic arsenite oxidisers. The Aio of GM1 is functional over a broad temperature range and its expression was found to be constitutively expressed and up-regulated in the late-log phase of growth. The data presented here contribute to a better understanding of arsenite oxidation and how the GM1 Aio is able to function at low temperatures.

**Identification of the *aio* gene cluster**

The *aioA* gene of GM1 was mutated by targeted gene disruption generating GM1-A. This mutant was unable to oxidise arsenite and did not exhibit detectable Aio activity (using DCPIP as the electron acceptor) in total cell extracts (data not shown), confirming that *aioA* confers an arsenite-oxidising phenotype in GM1. Mutagenesis of *aioA* facilitated the cloning of a 5.3 kb fragment which was sequenced. The 5307 bp sequence contains four complete and one partial open reading frame: this includes a putative phage integrase (partial sequence), the arsenite oxidase small subunit (*aioB*), the arsenite oxidase large catalytic subunit (*aioA*), a putative c-type cytochrome (cytC) and a nitroreductase (Fig. 1). These genes are transcribed in the same direction. No consensus sequence for a promoter was identified. Genes involved in the regulation of arsenite oxidation (*i.e. aioXSR*) were not identified but this is not surprising given that arsenite oxidation in GM1 is constitutively expressed whereas in bacteria that contain *aioXSR* the expression of the *aioBA* operon is induced with arsenite.

The partial open reading frame (1059 nt of a possible 1428 nt encoding 353/476 amino acids) upstream of *aioB* was found to share homology with putative phage integrases from various *Betaproteobacteria* such as *Oxalobacteraceae* sp. str. IMCC9480 (59% identity over 172 amino acids) and *Capriavidus* (also known as *Kastonia* metallidurans) (40% identity over 317 amino acids). The GM1 integrase sequence however, did not contain the conserved C-terminal catalytic domain present in the sequences of the closely related phage integrases, indicating that it is unlikely to be functional. The *aioB* gene is found downstream of the partial integrase sequence and encodes an apoprotein of 179 amino acids (18 561 Da). The protein shares closest sequence identity with the AioB homologues in the *Betaproteobacteria* such as *Acidovorax* sp. str. NO-1 (73% identity), *A. faecalis* (57% identity) and *Herminiimonas arsenicoxydans* (61% identity) compared with the alphaproteobacterial sequence from NT-26 (40% identity). The sequence contains a conserved motif involved in binding the Rieske 2Fe–2S cluster and in the case of *A. faecalis* (not in NT-26) conserved residues involved in disulphide bond formation, Cys-X-His-X-Gly-Cys*-X*-Cys-X-Cys*-His (cluster ligands are in italics; the asterisked residues form a disulphide bond which bridges over the cluster, connecting the two cluster-binding loops). In common with all other AioB sequences the GM1 sequence contains a Tat signal sequence (1–36 amino acids) with the conserved RRFLK motif (RRFLK in GM1 AioB) which directs the transport of the fully folded AioB complex to the periplasm via the Tat pathway. A predicted signal cleavage site is present between amino acids 36 and 37 (i.e. ADA-AT) resulting in a processed protein of 14 733 Da. Downstream of *aioB* is *aioA* and it encodes a protein of 827 amino acid (91 690 Da unprocessed and 91 559 Da without N-terminal methionine). The GM1 AioA shares the highest sequence identity with that from *Acidovorax* sp. str. NO-1 (80% identity), *A. faecalis* (70% identity) and *Herminiimonas arsenicoxydans* (69% identity) compared with that from NT-26 (47% identity). The conserved motif, Cys*-X*-Cys*-X*-Cys-X-Ser70 involved in binding the 3Fe–4S cluster, is conserved, as are the amino acids implicated in binding arsenite (i.e. His197, Glu205, Arg421 and His425). Downstream of *aioB* is cytC, which encodes a putative c-type cytochrome of 104 amino acids (10 884 Da unprocessed) and contains a single CX3CH heme-binding motif suggesting the presence of a single heme c. The protein also
contains a general secretory pathway (Sec) signal sequence for its transport to the periplasm, with a predicted cleavage site between amino acids 22 and 23 (i.e. SFA-NL) resulting in a processed protein of 8503 Da. The putative cytochrome may act as a physiological electron acceptor to the GM1 Aio as was observed for the c_{552} cytochrome encoded by the cytC gene in the aio cluster of NT-26.\textsuperscript{15} The putative GM1 cytochrome and nitroreductase did not show significant similarity to cytochrome and nitroreductase encoding genes in other aio gene clusters.

### Purification and characterisation of the arsenite oxidase

The Aio from GM1 was purified from the periplasm by a two-step ammonium sulphate precipitation (50% and 75%) followed by cation-exchange and size-exclusion chromatography. The Aio was enriched 32.7-fold (Table 1). The purified Aio consisted of two heterologous subunits of 88 kDa (AioA) and 15 kDa (AioB) (Fig. 2), and had a native molecular mass of 105.5 kDa (determined by gel filtration chromatography) indicating that the enzyme is a heterodimer (a_{2}b_{1}). The oligomeric state of the GM1 Aio is like that of A. faecalis\textsuperscript{,23} Arthrobacter sp. str. 15b\textsuperscript{24} and Ralstonia sp. str. 22\textsuperscript{14} but varies from that of NT-26\textsuperscript{25} and Hydrogenophaga sp. str. NT-14\textsuperscript{26} which form oligomers of a_{2}b_{1} and a_{1}b_{1}, respectively.

Purified GM1 Aio was analysed for metal cofactors using ICP-MS and was found to contain Mo (1.2 mol mol\textsuperscript{-1} enzyme) and Fe (6 mol mol\textsuperscript{-1} enzyme), indicating that like the mesophilic enzymes, the GM1 Aio contains Mo at the active site and two Fe–S clusters, which was also confirmed by sequence analyses (see above). The enzyme had a K_{m} for arsenite of 111.70 ± 0.88 µM and a V_{max} of 12.16 ± 0.30 µmol arsenite oxidised min mg\textsuperscript{-1}, corresponding to a K_{cat} of 21.38 ± 0.52 s\textsuperscript{-1} (based on a native molecular mass of 105.5 kDa). All three of these values are the highest observed for any Aio purified to date, when DCPIP was used as the electron acceptor. The higher K_{m} value shows that the GM1 Aio has a lower affinity for arsenite than the mesophilic enzymes, while the high V_{max} value is at least double that of the most active mesophilic Aio (i.e. that of NT-14).\textsuperscript{14,25,26}

A variety of e-type cytochromes and the copper-containing protein azurin can serve as electron acceptors to the Aio. NT-26 cytochrome c_{552} (electron acceptor to the NT-26 Aio),\textsuperscript{15} commercially purchased horse heart cytochrome c and Pseudomonas aeruginosa azurin, were tested for their ability to accept electrons from the GM1 Aio. Cytochrome c_{552} and horse-heart cytochrome c were not reduced by the GM1 Aio in the presence of arsenite (ESI,\textsuperscript{†} Fig. S1 and S2). The oxidised P. aeruginosa azurin exhibited a characteristic absorption band at 625 nm which disappeared upon its reduction in the presence of the GM1 Aio and arsenite (Fig. 3). Azurin was not reduced by either the Aio or arsenite alone (ESI,\textsuperscript{†} Fig. S3). The Aio of A. faecalis and Ralstonia sp. str. 22 can also use azurin as the electron acceptor but like the GM1 Aio are unable to use horse heart cytochrome c and the NT-26 c_{552} and horse heart cytochrome c cannot use azurin.\textsuperscript{15} The reason why the enzymes react differently with the various electron acceptors is presently unknown, but it appears to be unrelated to the redox potentials of the Rieske cluster.\textsuperscript{14,15,27}

### Cold adaptation of GM1 Aio

GM1 is a psychrotolerant arsenite oxidiser with a growth range between 0–20 °C. We therefore tested the effect of temperature on Aio activity making comparisons with the mesophilic enzyme from the only organism with a solved X-ray crystal structure A. faecalis.\textsuperscript{12} The enzyme from A. faecalis was purified after successful heterologous expression in E. coli. GM1 Aio had a maximum observed activity at 45 °C (13.8 U mg\textsuperscript{-1}), which was reduced to 8.0 U mg\textsuperscript{-1} at 60 °C and 9.2 U mg\textsuperscript{-1} at 10 °C corresponding to reductions of 42% and 33% of maximum observed activity, respectively (Fig. 4). In contrast, the Aio from

### Table 1 Purification of the GM1 Aio

| Purification step | Total protein (mg) | Total activity (U) | Specific activity (U mg\textsuperscript{-1}) | Purification [-fold] |
|------------------|--------------------|--------------------|---------------------------------------------|---------------------|
| Total cell extract | 74.4               | 26.83              | 0.36                                        | 1                   |
| Periplasm         | 12.9               | 12.71              | 1.02                                        | 2.8                 |
| Desalting        | 6.74               | 12.94              | 1.92                                        | 5.3                 |
| Cation exchange  | 0.51               | 3.73               | 7.32                                        | 20.3                |
| Gel filtration    | 0.14               | 1.65               | 11.79                                       | 32.7                |

The GM1 Aio was purified from the periplasm after the preparation of spheroplasts. The periplasm was fractionated by ammonium sulphate precipitation and the Aio-containing fraction desalted and purified by cation exchange and gel filtration chromatography.
A. faecalis had a maximum observed activity at 65 °C (8.1 U mg⁻¹), which was reduced to 7.3 U mg⁻¹ at 75 °C and 1.2 U mg⁻¹ at 10 °C, corresponding to reductions of 10% and 75% of maximum observed activity, respectively. As can be seen in Fig. 4, the GM1 Aio was active at lower temperatures (Fig. 4). The fact that the GM1 Aio had a lower optimum temperature (45 °C) than the A. faecalis enzyme (65 °C) and was also more active at lower temperatures is a common trait of cold-adapted enzymes.28

The properties that make enzymes cold-adapted are well known.28,29 The rate of an enzyme-catalysed reaction will change exponentially with a change in temperature hence temperature is in the exponent of the Arrhenius equation. Temperature is a function of activation energy and so a decrease in activation energy will make a reaction less dependent on temperature. In general, cold-adapted enzymes have lower activation energies than their mesophilic homologues increasing their activity at lower temperatures, which results from reduced enthalpy-requiring conformational changes needed to achieve the enzyme-substrate transition complex. The reduction in enthalpy-requiring changes often manifests itself as an increase in overall enzyme flexibility or localised flexibility around the active site, however, the increase in flexibility also decreases the protein’s stability.28,29 The increase in flexibility to achieve increased reaction rates means that often cold-adapted enzymes also have decreased affinity for the substrate (i.e. higher $K_{m}$) compared to their mesophilic homologues. An increased reaction rate and a decreased affinity for arsenite are observed for the GM1 Aio when compared to the mesophilic homologues suggesting that the former has increased flexibility.

Homology modelling of GM1 Aio

To investigate the molecular basis of cold-adaptation in the GM1 Aio, a model was built of the enzyme using the A. faecalis Aio crystal structure as a template. The model shows that the majority of amino acid differences between the two enzymes occur on the surface of the enzyme and that the entry channel to the active site is well conserved (Fig. 5). Destabilising effects on the structure, caused by amino acid differences between the GM1 and A. faecalis Aio were predicted using the SAAPdap pipeline of SAAPdb.32 44 amino acid differences (40 in AioA and 4 in AioB) were predicted to have destabilising structural effects on GM1 Aio, and are summarised in Table 2. It should be noted that as the analysis treats each amino acid difference as an individual mutation, many structural changes may be compensated by other changes. Increased flexibility/decreased stability of cold-adapted enzymes can be caused by several structural changes, including a decrease in stabilising bonds (H-bonds, van der Waals interactions and salt bridges), an increase in the surface hydrophobicity and a decrease in the core hydrophobicity. The SAAPdap analysis shows that a decrease in H-bonds and insertion

---

**Fig. 3** Oxidised and reduced spectra of P. aeruginosa azurin. Oxidised azurin (solid line) was reduced (dashed line) in the presence of the GM1 Aio and arsenite.

**Fig. 4** Temperature-activity profiles of the GM1 and A. faecalis arsenite oxidases. Percentage of maximum activity is plotted as a function of temperature of GM1 (●) and A. faecalis (○) Aio. Data points and error bars represent mean and standard deviation of at least three assays, respectively.

**Fig. 5** Space-filling homology model of GM1 Aio. The channel to the active site is boxed. Conserved residues between the GM1 and A. faecalis structure are blue; different residues are green.
of hydrophilic residues into the core are the major destabilising factors in the GM1 Aio. Of the 44 structure-affecting amino acid differences between GM1 and the \textit{A. faecalis} Aio, eight amino acids are unique to GM1 that appear to be conserved, or are synonymous, in sequences of \textit{A. faecalis}, NT-26 (a mesophilic alaphaproteobacterium with a similar Aio temperature-activity profile to \textit{A. faecalis});\textsuperscript{33} and the thermophilic arsenite oxidiser \textit{Thermus thermophilus} str. HB8.\textsuperscript{34} Of these eight amino acids, all in AioA, five introduce hydrophilic residues into the core of the structure: C32: Val-Thr; C231: Ile-Thr; C312: Gly-Thr; C469: Leu-Ala; C496: Leu-Thr.  

**Table 2** Destabilising structural effects of amino acid differences between GM1 and \textit{A. faecalis} Aio identified by SAAPdasp analysis

| Structural effect | No. of amino acid differences |
|-------------------|------------------------------|
| H Bond\textsuperscript{a} | 22 |
| Core Philic\textsuperscript{b} | 10 |
| Surface Philic\textsuperscript{c} | 6 |
| Buried Charge\textsuperscript{d} | 6 |
| Interface\textsuperscript{e} | 5 |
| Binding\textsuperscript{f} | 4 |
| Clash\textsuperscript{g} | 6 |
| Voids\textsuperscript{h} | 4 |
| Glycine\textsuperscript{i} | 1 |

\textsuperscript{a} Disrupts a hydrogen bond. \textsuperscript{b} Introduces a hydrophilic residue into the protein core. \textsuperscript{c} Introduces a hydrophobic residue on the surface. \textsuperscript{d} Introduces or removes a charged residue from the protein core. \textsuperscript{e} Occurs at an interface according to difference in solvent accessibility. \textsuperscript{f} Shows a specific binding interaction (hydrogen bond or van der Waals contact) at an interface. \textsuperscript{g} Replacement sidechain clashes with its surroundings. \textsuperscript{h} Introduces a void into the protein core. \textsuperscript{i} Parent residue was a glycine with a backbone conformation not favoured for other residues.

**Experimental**

**GM1 growth conditions**

GM1 was grown in a Minimal Salts Medium (MSM) containing 0.04\% yeast extract in the absence or presence of 5 mM arsenite as described previously.\textsuperscript{18} All incubations were performed at 0 °C unless stated otherwise. Arsenic analyses were determined as described previously.\textsuperscript{18} The GM1-A strain, in which \textit{aioA} was mutated, was grown in the presence of 5 μg ml\textsuperscript{-1} kanamycin. For the preparation of cell extracts and the purification of the Aio, GM1 was grown in the absence of arsenite in 2 L batch cultures (in 5 L flasks) until late-log phase (72 h; OD\textsubscript{600} 0.15–0.17).

**Mutagenesis of \textit{aioA}**

The GM1 \textit{aioA} gene was disrupted by targeted gene disruption as has been done previously.\textsuperscript{15,25} Briefly, a ~0.5 kb portion of the \textit{aio} gene\textsuperscript{18} was cloned into the suicide plasmid pJP5603 (Km\textsuperscript{R}).\textsuperscript{36} The recombinant plasmid was transformed into \textit{Escherichia coli} str. S17-1 \textit{pir}\textsuperscript{37} and transferred into a spontaneous rifampicin-resistant mutant of GM1 (GM1-R) by filter mating at 20 °C for 24 h on a Luria Bertani (LB) agar plate. The conjugation mixture was plated on MSM containing 1.5% purified agar (Oxoid), 0.04% yeast extract (Oxoid), 100 μg ml\textsuperscript{-1} rifampicin and 5 μg ml\textsuperscript{-1} kanamycin. The transconjugants were purified and selected for their ability to oxidise 5 mM arsenite in MSM with 0.04% yeast extract as described previously.\textsuperscript{18}

**Cloning and sequencing of the \textit{aio} gene cluster**

The \textit{aio} gene cluster was cloned by a ‘plasmid rescue’ technique. Genomic DNA from GM1-A was isolated using the Wizard\textsuperscript{R} genomic DNA purification kit (Promega) and digested with the restriction enzyme Clal. The linear fragments were circularised with T4 DNA ligase (Promega), transformed into \textit{E. coli} str. JM109 \textit{λpir}\textsuperscript{1} by electroporation and transformants containing pJP5603 and flanking GM1 genomic DNA were selected on LB containing 20 μg ml\textsuperscript{-1} Km. Both strands of the \textit{aio} gene cluster were sequenced by primer-walking. Sequencing was performed at the Wolfson Institute for Biomedical Research (WIBR) by capillary electrophoresis using a 3730XL Genetic Analyser with BigDye 3.1 (Applied Biosystems). Databases were searched using the BLAST suite (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and open reading frames (ORFs) allocated using ORF Finder (http://www.ncbi.nlm.nih.gov/projects/gorf/). Signal peptide motifs were identified using Signal\textsuperscript{P} and TatP.\textsuperscript{39} The GenBank accession number for the sequence of the GM1 \textit{aio} gene cluster is EU106602.

**Preparation of GM1 cell fractions**

Total cell extracts were prepared as described previously\textsuperscript{6} using the previously determined optimum buffer of the Aio with the artificial electron acceptor 2,6-dichlorophenolindophenol (DCPIP), 50 mM MES (pH 5.5).\textsuperscript{18} For the preparation of spheroplasts, cells were harvested and washed and spheroplasts prepared as described previously\textsuperscript{40} with the following modifications: (1) the harvested cells were suspended in ice-cold 750 mM sucrose, 30 mM Tris/HCl (pH 8) at a ratio of 0.5 g wet cells per ml, (2) lysozyme was added at a concentration of 10 mg g\textsuperscript{-1} wet cells, (3) cells were incubated with lysozyme at room temperature for 1 h, (4) after the addition of 15 mM EDTA (pH 8, 0 °C), the suspension was incubated at 0 °C for 30 min.

**Purification of the GM1 Aio**

The GM1 Aio was purified from the periplasm after spheroplast preparation. The periplasm was subjected to two ammonium sulphate precipitation steps, 30% and 75% saturation (0 °C). The protein pellet was suspended in 50 mM MES (pH 5.5) and desalted using a PD-10 desalting column (GE Healthcare).
according to the manufacturer’s instructions, with 50 mM MES (pH 5.5) as the elution buffer. The sample (3.5 ml) was passed through a 0.22 μm filter (Millipore) and concentrated using a Vivaspin 20 device (10 000 MWCO) (Sartorius Stedium Biotech) to < 500 μl. The sample was applied to a SP sepharose fast flow HiPrep 16/10 cation exchange column (GE Healthcare) which had been pre-equilibrated with 50 mM MES (pH 5.5). Chromatography was carried out at room temperature (20–25 °C) at a flow rate of 5 ml min⁻¹. The Aio was eluted using a 1 M NaCl gradient in 50 mM MES (pH 5.5). The NaCl gradient was as follows: (1) 0 M for 2.25 column volumes and (2) a linear increase to 0.6 M over 12 column volumes. Fractions containing Aio activity were pooled and concentrated. The sample was then applied to a Superdex 200 10/300 gel filtration column (GE Healthcare) pre-equilibrated with 50 mM MES, 150 mM NaCl (pH 5.5). Chromatography was carried out at a flow rate of 0.5 ml min⁻¹ at room temperature. Fractions containing Aio activity were pooled and de-salted using a PD-10 desalting column.

**Heterologous expression and purification of the Alcaligenes faecalis Aio**

The aioB and aioA (aioBA) genes from *A. faecalis* were amplified without the native twin-arginine translocation (Tat) leader sequence using the following primers: Forward; 5'-GCTCTAGAGCTACATCTGAGTACCCGACGGGACTGCC-3' and Reverse: 5'-CGCTGAGTGACGCAACGGCAGGGCGCTTTT-3'. The restriction enzymes *Xba*I and *Xho*I (underlined above) were used for cloning into the expression vector, pPROEX-HTb in frame with the N-terminal histidine tag. The PCR reaction was performed for 35 cycles using the KOD proofreading DNA polymerase (Applied Biosystems) with a 55 °C annealing temperature as per the manufacturer's instructions.

The *E. coli* JM109 *λpir* strain was used for Aio expression. Expression of the Aio involved growing *E. coli* aerobically at 21 °C for 24 h in LB containing 100 μg ml⁻¹ Ap, 40 μM IPTG (isopropyl β-D-1-thiogalactopyranoside) and 1 mM Na₂MoO₄.

Cells were harvested by centrifugation at 5464 × g for 10 min (4 °C) and the pellets washed by suspending them in binding buffer (20 mM KH₂PO₄, 500 mM NaCl, 20 mM imidazole, pH 7.3). The cells were centrifuged at 15 180 × g for 10 min (4 °C) and the pellet resuspended in binding buffer (10 ml g⁻¹ wet weight cells). Cells were disrupted by two passages through a French press (13 000 psi) and the cell debris removed by centrifugation at 30 000 × g (4 °C). The supernatant was filtered through a 0.22 μm filter (Millipore) and loaded onto a HisTrap-Ni Sepharose High Performance column (GE Healthcare) that had been pre-equilibrated with binding buffer. Chromatography was carried out at 1 ml min⁻¹ at room temperature and unbound proteins removed with 30 column volumes of binding buffer followed by a gradient of 30 column volumes with elution buffer (20 mM KH₂PO₄, 500 mM NaCl, 500 mM imidazole, pH 7.3). Fractions that contained Aio activity (Aio was eluted at 295 mM imidazole) were pooled and the sample was concentrated using a Vivaspin 20 (MWCO 50 000) (Sartorius Stedium Biotech) centrifugal concentrator and loaded on to a Superdex 200 10/300 gel filtration column (GE Healthcare) that had been pre-equilibrated with 50 mM MES, 150 mM NaCl (pH 6.0). Gel filtration chromatography was carried out at a flow rate of 0.5 ml min⁻¹ at room temperature. Fractions containing Aio activity were pooled and the buffer exchanged using a PD-10 desalting column (GE Healthcare), according to the manufacturer’s instructions, with 50 mM MES (pH 6.0) serving as the elution buffer. The sample was concentrated using a Vivaspin 20 (MWCO 50 000) (Sartorius Stedium Biotech) and Micron YM-30 (Millipore) centrifugal concentrators and enzyme assays performed immediately.

**Enzyme assays and protein determination**

Aio and malate dehydrogenase enzyme assays were done as described previously. The results of the kinetics are from two independent experiments with three replicates for each arsenite concentration tested, so there are a total of 6 values for each concentration. All assays were performed at 24 °C unless otherwise stated. The temperature of the enzyme assays was controlled with a Varian Cary dual cell Peltier. Reaction mixtures were incubated at the cell temperature for 5 minutes prior to the addition of arsenite.

Protein concentrations were determined using the Bradford method and BioRad reagent according to the manufacturer’s instructions and bovine serum albumin served as the standard.

The oxidised and reduced spectra of the *Rhizobium* sp, str. NT-26 cytochrome *c*₅₅₂, horse heart cytochrome *c* (Sigma), and *P. aeruginosa* azurin (Sigma) were recorded as described previously with 20 μg of electron acceptor and 3 μg of Aio.

**Subunit composition and cofactor analysis**

SDS-PAGE of denatured protein was performed as described previously with low molecular weight standards (GE Healthcare). For cofactor analysis purified Aio was prepared as described previously and analysed for Fe, Co, Ni, Cu, Zn, Mo and W, by inductively coupled plasma-mass spectrometer (ICP-MS) (Varian) at the Mineralogy Department, Natural History Museum, London, UK.

**Homology modelling**

Modelling of the GM1 Aio was performed with Modeller using the *A. faecalis* Aio crystal structure as a template (PDB code 1g8j, chains C and D). The alignment was hand-modified to accommodate the insertion at C505–C506 and deletion at C651 to minimise disruption of the parent structure. Structural effects of amino acid differences were analysed using the SAAPdap pipeline of the SAAPdb database treating each difference as a single mutation in the *A. faecalis* structure.

**Conclusions**

GM1 is a psychrotolerant arsenite oxidiser that possesses an Aio that is adapted to function at cold temperatures. Compared to its mesophilic counterparts the GM1 Aio has the same subunit composition and contains the same cofactors but it has a much higher reaction rate and a lower affinity for arsenite. Cold-adaptation of GM1 Aio is probably caused by an increase in the enzyme’s flexibility which appears to result from changes in the overall protein structure and not by alterations specific to
the active site or cofactors. The insertion of hydrophilic residues into the core is a major destabilising factor in the GM1 Aio. The aerobic arsenite oxidase is an ancient bioenergetic enzyme and understanding the reaction mechanism from psychrophilic, mesophilic and thermophilic homologues will not only improve our understanding of its evolution but should also aid our development of a broad-temperature range arsenite biosensor.

Acknowledgements

THO was supported by a Natural Environment Research Council PhD studentship (G0800112). We would like to thank Barbara Schoep-Cothenen and Gretchen Anderson for supplying the A. faecalis strain and helpful discussions. We would also like to thank Stanislav Strekopytov for performing the metal analyses of the arsenite oxidase.

References

1. J. O. Nriagu, in Environmental chemistry of arsenic, ed. W. T. Frankenberger, Marcel Dekker, New York, 2002, ch. 1, pp. 1–26.
2. P. L. Smedley and D. G. Kinniburgh, Appl. Geochem., 2002, 17, 517.
3. M. F. Hughes, Toxicol. Lett., 2002, 133, 1.
4. P. Ravenscroft, H. Brammer and K. Richards, Arsenic pollution a global synthesis, Wiley-Blackwell, UK, 2009.
5. D. K. Nordstrom, Science, 2002, 296, 2143.
6. J. M. Santini, L. I. Sly, R. D. Schnagl and J. M. Macy, Appl. Environ. Microbiol., 2000, 66, 92.
7. R. S. Oremland and J. F. Stolz, Science, 2003, 300, 939.
8. H. H. Green, S. Afr. J. Sci., 1918, 14, 465.
9. T. H. Osborne and J. M. Santini, in The Metabolism of Arsenite, ed. J. M. Santini and S. A. Ward, CRC Press, Boca Raton, Florida, 2012, ch. 5, pp. 61–69.
10. M. C. Lett, D. Muller, D. Liévrément, S. Silver and J. M. Santini, J. Bacteriol., 2012, 194, 207.
11. A. G. McEwan, J. P. Ridge, C. A. McDevitt and P. Hugenholtz, Geomicrobiol. J., 2002, 9, 3.
12. P. J. Ellis, T. Conrads, R. Hille and P. Kuhn, Appl. Geochem., 2008, 23, 661.
13. T. H. Osborne and J. M. Santini, in The Metabolism of Arsenite, ed. J. M. Santini and S. A. Ward, CRC Press, Boca Raton, Florida, 2012, ch. 5, pp. 61–97.
14. A. Lieutaud, R. van Lis, S. Duval, L. Capowiez, D. Muller, R. Lebrun, S. Lignon, M. L. Fardue, M. C. Lett, W. Nitschke and B. Schoep-Cothenen, J. Biol. Chem., 2010, 285, 20442.
15. J. M. Santini, U. Kappler, S. A. Ward, M. J. Honeychurch, R. N. vanden Hoven and P. V. Bernhardt, Biochim. Biophys. Acta, 2007, 1767, 189.
16. S. Sardiwal, J. M. Santini, T. H. Osborne and S. Djordjevic, FEMS Microbiol. Lett., 2010, 313, 20.
17. G. Liu, M. Liu, E. H. Kim, W. S. Maaty, B. Bothner, B. Lei, C. Rensing, G. Wang and T. R. McDermott, Environ. Microbiol., 2012, 14, 1624.
18. T. H. Osborne, H. E. Jamieson, K. A. Hudson-Edwards, D. K. Nordstrom, S. R. Walker, S. A. Ward and J. M. Santini, BMC Microbiol., 2010, 10, 205.
19. Y. Huang, H. Li, C. Rensing, K. Zhao, L. Johnstone and G. Wang, J. Bacteriol., 2012, 194, 1635.
20. S. Koechler, J. Cleiss-Arnold, C. Proux, O. Sismeiro, M. A. Dillies, F. Goulhen-Chollet, F. Hommais, D. Liévrément, F. Arsène-Ploetze, J. Y. Coppée and P. N. Bertin, BMC Microbiol., 2010, 10, 53.
21. D. R. Kashyap, L. M. Botero, W. L. Franck, D. J. Hassett and T. R. McDermott, J. Bacteriol., 2006, 188, 1081.
22. N. R. Stanley, T. Palmer and B. C. Berks, J. Biol. Chem., 2000, 275, 11591.
23. G. L. Anderson, J. Williams and R. Hille, J. Biol. Chem., 1992, 267, 23674.
24. K. S. Prasad, V. Subramanian and J. Paul, Biometals, 2009, 22, 711.
25. J. M. Santini and R. N. vanden Hoven, J. Bacteriol., 2004, 186, 1614.
26. R. N. vanden Hoven and J. M. Santini, Biochim. Biophys. Acta, 2004, 1656, 148.
27. S. Duval, A. L. Ducluzeau, W. Nitschke and B. Schoep-Cothenen, BMC Evol. Biol., 2008, 8, 206.
28. G. Feller and C. Gerday, Nat. Rev. Microbiol., 2003, 1, 200.
29. K. S. Siddiqui and R. Cavicchioli, Annu. Rev. Biochem., 2006, 75, 403.
30. D. Georlette, B. Damien, V. Blaise, E. Depiereux, V. N. Uversky, C. Gerday and G. Feller, J. Biol. Chem., 2003, 278, 37015.
31. S. D’amico, J. C. Marx, C. Gerday and G. Feller, J. Biol. Chem., 2003, 278, 7891.
32. J. M. Hurst, L. E. M. McMillan, C. T. Porter, J. Allen, A. Fakorede and A. C. R. Martin, Hum. Mutat., 2009, 30, 616.
33. T. P. Warelow and J. M. Santini, Unpublished work.
34. T. M. Gihring, G. K. Druschel, R. B. McClesky, R. J. Hamers and J. F. Banfield, Environ. Sci. Technol., 2001, 19, 3857.
35. P. J. Simpson and R. Codd, Biochim. Biophys. Res. Commun., 2011, 414, 783.
36. R. J. Penfold and J. M. Pemberton, Gene, 1992, 118, 145.
37. R. Simon, U. Pfeifer and A. Pu¨hler, Biotechnology, 1983, 1, 784.
38. T. N. Petersen, S. Brunak, G. von Heijne and H. Nielsen, Nat. Methods, 2011, 8, 785.
39. D. Bendtsen, H. Nielsen, D. Widdick, T. Palmer and S. Brunak, BMC Bioinf., 2005, 6, 167.
40. T. Krafft and J. M. Macy, Eur. J. Biochem., 1998, 255, 647.
41. M. M. Bradford, Anal. Biochem., 1976, 72, 248.
42. N. Eswar, M. A. Marti-Renom, B. Webb, M. S. Madhusudhan, D. Eramian, M. Shen, U. Pieper and A. Sali, Curr. Protoc. Bioinformatics, 2006, Suppl. 15, 5.6.1.
43. R. van Lis, W. Nitschke, S. Duval and B. Schoep-Cothenen, in The Metabolism of Arsenite, ed. J. M. Santini and S. A. Ward, CRC Press, Boca Raton, Florida, 2012, ch. 10, pp. 125–144.
44. E. Lebrun, M. Brugna, F. Baymann, D. Muller, D. Liévrément, M.-C. Lett and W. Nitschke, Mol. Biol. Evol., 2003, 20, 686.